A



B

Treatment	SUCRA	PrBest	Mean rank
Placebo	91.1	75.9	1.8
GLP-1RA	77.9	4.3	3.0
DPP4i	51.1	2.1	5.4
TZD	49.7	8.2	5.5
Met+DPP4i	47.8	4.1	5.7
Met	43.0	0.4	6.1
DPP4i+SGLT2i	39.2	1.7	6.5
Met+TZD	37.8	1.7	6.6
SGLT2i	34.2	1.3	6.9
SU	28.3	0.3	7.5

Supplementary Fig. 5. Network geometry (A), rank test (B), the results of network and pairwise meta-analysis (C) for odds ratios of any adverse events of antidiabetic treatments. (A) The global test for inconsistency yielded a *P* value of 0.8471, indicating no evidence of inconsistency in the network. (B) The table presents the results of the network rank test (surface under the cumulative ranking curve [SUCRA], probability of being the best [PrBest], mean rank) for different antidiabetic treatments, ordered by mean rank. (C) Network (upper right side) and pairwise (lower left side) meta-analytic results are depicted for odds ratios of any adverse events of antidiabetic treatments. The outcome of meta-analysis is expressed as effect size with 95% credible intervals in the case of network meta-analysis and 95% confidence intervals in the case of pairwise meta-analysis. Each value and interval refer to the efficacy of the top-row treatment compared to the left column. The order of antidiabetic treatments in this league table is presented in order of the mean rank results. TZD, thiazolidinedione; SGLT2i, sodium-glucose cotransporter-2 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; DPP4i, dipeptidyl peptidase-4 inhibitor; Met, metformin; SU, sulfonylurea.

(*Continued to the next page*)

Supplementary Fig. 5. Continued

C

	Placebo	GLP-1RA	DPP4i	TZD	Met+DPP4i	Met	DPP4i+SGLT2i	Met+TZD	SGLT2i	SU
Placebo	Placebo	4.83 (0.57–41.19)	3.91 (0.47–32.38)	3.93 (0.38–40.89)	3.95 (0.48–32.69)	3.83 (0.44–33.31)	4.43 (0.50–39.35)	4.59 (0.52–40.39)	4.65 (0.52–41.34)	5.29 (0.63–44.51)
GLP-1RA	0.80 (0.60–1.05) I^2=33.2% 3 studies	GLP-1RA	0.81 (0.27–2.45)	0.81 (0.26–2.50)	0.82 (0.27–2.47)	1.01 (0.32–3.22)	0.92 (0.27–3.16)	0.95 (0.28–3.22)	0.96 (0.28–3.32)	1.09 (0.63–1.91)
DPP4i	0.92 (0.76–1.12) I^2=34.9% 12 studies		DPP4i	1.00 (0.23–4.30)	1.01 (0.35–2.87)	1.06 (0.36–3.07)	1.13 (0.65–1.97)	1.17 (0.70–1.97)	1.19 (0.68–2.08)	1.35 (0.46–3.98)
TZD			0.79 (0.52–1.20) I^2=0.0% 1 study	TZD	1.01 (0.23–4.30)	0.29 (0.03–2.42)	1.13 (0.24–5.34)	1.17 (0.25–5.46)	1.18 (0.25–5.61)	1.35 (0.45–4.03)
Met+DPP4i	0.25 (0.03–2.05) I^2=0.0% 1 study		0.99 (0.37–2.69) I^2=0.0% 1 study		Met+DPP4i	1.13 (0.41–3.13)	1.12 (0.34–3.66)	1.16 (0.36–3.73)	1.18 (0.36–3.85)	1.34 (0.45–3.94)
Met	0.22 (0.03–1.79) I^2=0.0% 1 study	1.08 (0.81–1.45) I^2=0.0% 1 study	0.84 (0.68–1.04) I^2=0.0% 3 studies	0.99 (0.79–1.26) I^2=0.0% 3 studies	0.89 (0.34–2.34) I^2=0.0% 1 study	Met	0.88 (0.32–2.43)	1.03 (0.33–3.22)	1.08 (0.71–1.66)	5.38 (0.62–47.04)
DPP4i+SGLT2i			0.88 (0.56–1.41) I^2=0.0% 1 study				DPP4i+SGLT2i	1.04 (0.48–2.22)	1.05 (0.64–1.72)	1.19 (0.35–4.03)
Met+TZD			0.85 (0.56–1.29) I^2=0.0% 1 study	1.08 (0.79–1.46) I^2=0.0% 1 study				Met+TZD	1.01 (0.47–2.17)	1.15 (0.35–3.82)
SGLT2i	0.96 (0.81–1.14) I^2=0.0% 6 studies		0.83 (0.65–1.07) I^2=0.0% 3 studies				0.95 (0.65–1.40) I^2=0.0% 1 study		SGLT2i	1.14 (0.34–3.84)
SU		1.25 (0.92–1.71) I^2=0.0% 1 study		0.85 (0.58–1.23) I^2=41.6% 3 studies		0.74 (0.343–1.64) I^2=85.4% 2 studies				SU